- Home
- CORT
as 01-21-2025 4:00pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 5.6B | IPO Year: | N/A |
| Target Price: | $75.25 | AVG Volume (30 days): | 773.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.26 | EPS Growth: | 57.97 |
| 52 Week Low/High: | $20.84 - $62.22 | Next Earning Date: | 02-13-2025 |
| Revenue: | $628,555,000 | Revenue Growth: | 39.67% |
| Revenue Growth (this year): | 46.29% | Revenue Growth (next year): | 17.09% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Robb Gary Charles | CORT | Chief Business Officer | Jan 2 '25 | Sell | $50.50 | 11,000 | $555,551.70 | 20,119 | |
| Maduck Sean | CORT | See Remarks | Jan 2 '25 | Sell | $50.39 | 20,000 | $1,007,800.00 | 85,318 | |
| Swisher Daniel N JR | CORT | Director | Dec 10 '24 | Sell | $59.46 | 2,200 | $130,812.00 | 0 | |
| Robb Gary Charles | CORT | Chief Business Officer | Nov 22 '24 | Sell | $56.20 | 2,609 | $146,625.80 | 20,119 | |
| Lyon Joseph Douglas | CORT | See Remarks | Nov 22 '24 | Sell | $56.72 | 1,411 | $80,031.92 | 8,494 | |
| Swisher Daniel N JR | CORT | Director | Nov 11 '24 | Sell | $59.88 | 2,200 | $131,736.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Nov 1 '24 | Sell | $48.97 | 10,000 | $489,700.00 | 5,796 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)
Insider Monkey
4 days ago
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?
Argus Research
7 days ago
CORT: What does Argus have to say about CORT?
Simply Wall St.
15 days ago
Discover 3 US Growth Stocks With Strong Insider Ownership
Insider Monkey
15 days ago
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance
Zacks
22 days ago
Corcept Submits Application for Another Cushing's Syndrome Drug
MT Newswires
22 days ago
Corcept Therapeutics Files New Drug Application for Relacorilant
Business Wire
22 days ago
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.